Bicara Therapeutics Inc. · NASDAQ:BCAX
Cohlhepp Ryan sold 28,750 Bicara Therapeutics Inc. shares (Form 4)
Traded Jul 8 to Jul 9, 2026 · Filed Jul 10, 2026
From Jul 8 to Jul 9, 2026, Cohlhepp Ryan (Director, President and COO) sold 28,750 Bicara Therapeutics Inc. shares at an average US$28.98 for US$833K under a trading plan, leaving 181,641 shares. Filed Jul 10, 2026 (Form 4).
- Sold
- 28,750 shares
- Price
- US$28.98 average (US$28.76 to US$30.35)
- Value
- US$833K
- Holding after
- 181,641 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director, President and COO
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | Common Stock | Option exercise | 18,750 | US$3.79 | 210,391 | Direct |
| Jul 8, 2026 | Common Stock | Sale | 22,833 | US$28.76 | 187,558 | Direct |
| Jul 8, 2026 | Common Stock | Sale | 4,306 | US$29.80 | 183,252 | Direct |
| Jul 8, 2026 | Common Stock | Sale | 1,075 | US$30.35 | 182,177 | Direct |
| Jul 9, 2026 | Common Stock | Sale | 536 | US$29.00 | 181,641 | Direct |
Source
Related
- Bicara Therapeutics Inc.
- Cohlhepp Ryan
- Bicara Therapeutics Inc. shareholders
- Form 4 · Cohlhepp Ryan · Sep 10, 2026
- Form 4 · Cohlhepp Ryan · Aug 12, 2026
- Form 4 · Cohlhepp Ryan · May 18, 2026
- Form 4 · Cohlhepp Ryan · Apr 17, 2026
- Schedule 13G/A · T. Rowe Price Investment Management, Inc. · Oct 7, 2026
- Schedule 13G/A · Janus Henderson Group PLC · Aug 13, 2026
- Form 4 · Hyep Ivan · Aug 12, 2026
- Form 4 · Mazumdar Claire · Aug 12, 2026
- Schedule 13G · BlackRock, Inc. · Jul 27, 2026